

CTI BIOPHARMA CORP

Form 4

February 26, 2016

**FORM 4****UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

Check this box  
if no longer  
subject to  
Section 16.  
Form 4 or  
Form 5  
obligations  
may continue.  
*See* Instruction  
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF  
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

## OMB APPROVAL

OMB  
Number: 3235-0287  
Expires: January 31,  
2005  
Estimated average  
burden hours per  
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**SINGER JACK W**

(Last) (First) (Middle)

3101 WESTERN AVENUE, SUITE  
600

(Street)

SEATTLE, WA 98121

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading  
Symbol

CTI BIOPHARMA CORP [ctic]

3. Date of Earliest Transaction  
(Month/Day/Year)

02/26/2016

4. If Amendment, Date Original  
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to  
Issuer

(Check all applicable)

☐ Director ☐ 10% Owner  
☒ Officer (give title below) ☐ Other (specify  
below)

EVP, Chief Scientific Officer

6. Individual or Joint/Group Filing(Check  
Applicable Line)  
☒ Form filed by One Reporting Person  
☐ Form filed by More than One Reporting  
Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/26/2016		S <sup>(1)</sup>		100	D	\$ 0.615
Common Stock	02/26/2016		S <sup>(1)</sup>		300	D	\$ 0.618
Common Stock	02/26/2016		S <sup>(1)</sup>		200	D	\$ 0.62
Common Stock	02/26/2016		S <sup>(1)</sup>		510	D	\$ 0.622
Common Stock	02/26/2016		S <sup>(1)</sup>		100	D	\$ 0.623

Edgar Filing: CTI BIOPHARMA CORP - Form 4

Common Stock	02/26/2016	<u>S</u> (1)	200	D	\$ 0.624	1,053,582	D
Common Stock	02/26/2016	<u>S</u> (1)	200	D	\$ 0.625	1,053,382	D
Common Stock	02/26/2016	<u>S</u> (1)	300	D	\$ 0.63	1,053,082	D
Common Stock	02/26/2016	<u>S</u> (1)	100	D	\$ 0.631	1,052,982	D
Common Stock	02/26/2016	<u>S</u> (1)	600	D	\$ 0.633	1,052,382	D
Common Stock	02/26/2016	<u>S</u> (1)	3,990	D	\$ 0.634	1,048,392	D
Common Stock	02/26/2016	<u>S</u> (1)	600	D	\$ 0.635	1,047,792	D
Common Stock	02/26/2016	<u>S</u> (1)	1,130	D	\$ 0.636	1,046,662	D
Common Stock	02/26/2016	<u>S</u> (1)	2,600	D	\$ 0.637	1,044,062	D
Common Stock	02/26/2016	<u>S</u> (1)	3,270	D	\$ 0.638	1,040,792	D
Common Stock	02/26/2016	<u>S</u> (1)	200	D	\$ 0.639	1,040,592	D
Common Stock	02/26/2016	<u>S</u> (1)	100	D	\$ 0.642	1,040,492	D
Common Stock	02/26/2016	<u>S</u> (1)	500	D	\$ 0.643	1,039,992	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3,	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction (Instr.
--	--	--------------------------------------	--	--------------------------------	---	--	---	--	--

4, and 5)

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Code V (A) (D)				

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
SINGER JACK W 3101 WESTERN AVENUE SUITE 600 SEATTLE, WA 98121	X		EVP, Chief Scientific Officer	

## Signatures

By: Louis A. Bianco, Attorney-in-fact For: Jack W. Singer 02/26/2016

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The sale was effected pursuant to a Rule 10b5-1 trading plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.